BCM
ACAD icon

Bluefin Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Bluefin Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,500
Closed -$7K – 662
2021
Q4 		$7K Buy
+14,500
New +$292K ﹤0.01% 820

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bluefin Capital Management's ACAD Position: Q1 2022 in Review

Bluefin Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2022, closing a stake of 159,596 shares — an estimated $3.73M sold.

Bluefin Capital Management first reported a position in ACAD in Q4 2021 and held it in 1 quarter. The position peaked at $3.73M in Q4 2021. 263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

  • Bluefin Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Bluefin Capital Management sold 159,596 Acadia Pharmaceuticals shares in Q1 2022, an estimated $3.73M.
  • Bluefin Capital Management first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Bluefin Capital Management's Acadia Pharmaceuticals position peaked at $3.73M in Q4 2021.
  • 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on Bluefin Capital Management's 13F filing for Q1 2022, filed 16 May 2022.